MS Society Scotland has welcomed the decision to approve the first ever drug for progressive multiple sclerosis (MS) for use on NHS Scotland.

Ocrelizumab (Ocrevus) has been given the green light by the Scottish Medicines Consortium for treating primary progressive MS where the condition is still early in terms of duration and disability and shows evidence of inflammation.

More than 11,000 people in Scotland have MS and around 65 each year are diagnosed with the primary progressive form.

Read more: Former Bankies part of group launching project to open homeless shelter

Ocrelizumab is the first and only treatment that can slow disability progression in this type of MS, where symptoms gradually worsen over time.

Morna Simpkins, director for MS Society Scotland, said: “This is great news and a hugely important development.”